Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
Summary
GlobalData's Medical Devices sector report, “Bioabsorbable Stents (BAS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Bioabsorbable Stents (BAS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Bioabsorbable stents are also known as bioreabsorbable or biodegradable coronary stents. The advantage of this stent is that it does not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in better drug delivery compared to metallic stents.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Bioabsorbable Stents (BAS) under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
About GlobalData
Introduction
Bioabsorbable Stents (BAS) Overview
Products under Development
Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
Table Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
Table Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
Bioabsorbable Stents (BAS) - Pipeline Products by Territory
Table Biotronik AG - Ongoing Clinical Trials Overview
Table Magmaris Bioresorbable Magnesium Scaffold - A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II
Table Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
Table Magmaris Bioresorbable Magnesium Scaffold - Biotroniks - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV
Table Magmaris Bioresorbable Magnesium Scaffold - Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI)
Table Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction with the Drug-eluting Resorbable Magnesium Scaffold: The BEST- MAG Multicentre Study (Belgian STsegment Elevation Myocardial Infarction Treatment with Resorbable Magnesium Scaffold)
Table Magmaris Bioresorbable Magnesium Scaffold - Retrospective, Observational Register to Investigate the Procedural and Post Procedural Implantation of Bioabsorbable Magnesium Scaffolds Magmaris (MAGIC Registry)
Table Magmaris Bioresorbable Magnesium Scaffold - Scaffold Implantation in Emilia-Romagna
Table DREAMS 3G System - BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries
Table DREAMS 3G System - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial
Biotronik SE & Co KG Company Overview
Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
Table Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
Table AMS-2 - Product Status
Table AMS-2 - Product Description
Biotyx Medical (Shenzhen) Co Ltd Company Overview
Biotyx Medical (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table Biotyx Medical (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table IBS Angel - Product Status
Table IBS Angel - Product Description
Table Biotyx Medical (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview
Table IBS Angel - A Prospective, Multi-center, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of Iron Bioresorbable Scaffold System (IBS Angel) in Patients with Pulmonary Artery Stenosis
Boston Scientific Corp Company Overview
Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table Boston Scientific Corp - Ongoing Clinical Trials Overview
Table Synergy Megatron Bioabsorbable Polymer (BP) Stent - A U.S. Post-Approval Study of the SYNERGYTM Everolimus- Eluting Platinum Chromium Coronary Stent System Evaluating the SYNERGY XLV (MEGATRON) Stent System
Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A First-in-man Study of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A Prospective, Multi-center, Single-arm Trial of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System in Patients with Coronary Artery Disease: IRONMAN-III
Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A Prospective, Multi-center, Single-blinded, Randomized Trial of the Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System in Patients with Coronary Artery Disease: IRONMAN-II
Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A Prospective, Non-randomized, Open-label, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System
Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - Feasibility, Efficacy and Safety of IBS for Implantation in the PDA in Duct-dependent Cyanotic CHD
Table MeRes100 - A Multi Center Randomized Control Study of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System in Treatment of Coronary Artery Disease Patients: MeRes - China
Table MeRes100 - A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions: MeRes-1 Extend
Table MeRes100 - To Compare the Safety and Performance of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions
Table Firesorb Bioresorbable Scaffold - A First-in-man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease: FUTURE-I
Table Firesorb Bioresorbable Scaffold - A Prospective Multicenter Single-arm Clinical Trial Assessing the Safety and Effectiveness of Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold for the Treatment of Coronary Artery Disease: FUTURE III
Table Firesorb Bioresorbable Scaffold - A Randomized Trial of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease: FUTURE-II
Minvasys SAS Company Overview
Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview
Table Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview
Table Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Status
Table Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Description
Table REVA Medical Inc - Ongoing Clinical Trials Overview
Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Expanded FANTOM II Clinical Study
Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Post Market Study of the FANTOM Sirolimus-eluting Bioresorbable Coronary Scaffold
Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Safety and Efficacy of the FANTOM ENCORE Sirolimuseluting Bioresorbable Scaffold for Treatment of De-novo Coronary Artery Disease: The ENCORE-I Study
Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Safety and Performance Study of the FANTOM Sirolimus-eluting Bioresorbable Coronary Scaffold
Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Vascular Healing Pattern, Vasoreactivity, and Quality of Life in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention with Sirolimus Eluting FANTOM Bioresorbable Vascular Scaffold with Long Term Clinical, Near Infrared Spectroscopy and Optical Coherence Tomography Follow-up: A FANTOM STEMI Pilot Study
Table Bioheart BRS System - A Randomized Controlled Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II
Table Bioheart BRS System - A Registry Trial of the Bioheart Rapamycin Drug-eluting Bioresorbable Coronary Stent System in Patients with Coronary Artery Disease: BIOHEART III
Table Bioheart BRS System - Study of Bioheart BRS System for the Treatment of Coronary Artery Disease
Shanghai Healing Medical Instruments Co Ltd Company Overview
Shanghai Healing Medical Instruments Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table Shanghai Healing Medical Instruments Co Ltd Pipeline Products & Ongoing Clinical Trials Overview